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Objectives: It is still debated if pre-existing minority drug-resistant HIV-1 variants (MVs) affect the virological
outcomes of first-line NNRTI-containing ART.
Methods: This Europe-wide case–control study included ART-naive subjects infected with drug-susceptible HIV-1
as revealed by population sequencing, who achieved virological suppression on first-line ART including one NNRTI.
Cases experienced virological failure and controls were subjects from the same cohort whose viraemia remained
suppressed at a matched time since initiation of ART. Blinded, centralized 454 pyrosequencing with parallel
bioinformatic analysis in two laboratories was used to identify MVs in the 1%–25% frequency range. ORs of
virological failure according to MV detection were estimated by logistic regression.
Results: Two hundred and sixty samples (76 cases and 184 controls), mostly subtype B (73.5%), were used for the
analysis. Identical MVs were detected in the two laboratories. 31.6% of cases and 16.8% of controls harboured
pre-existing MVs. Detection of at least one MV versus no MVs was associated with an increased risk of virological
failure (OR¼2.75, 95% CI¼1.35–5.60, P¼0.005); similar associations were observed for at least one MV versus
no NRTI MVs (OR¼2.27, 95% CI¼0.76–6.77, P¼0.140) and at least one MV versus no NNRTI MVs (OR¼2.41, 95%
CI¼1.12–5.18, P¼0.024). A dose–effect relationship between virological failure and mutational load was found.
Conclusions: Pre-existing MVs more than double the risk of virological failure to first-line NNRTI-based ART.
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Introduction
Antiretroviral drug resistance testing is one of the mainstays of the
clinical management of HIV-1 infection1 and is essential to inform
public health strategies to combat the HIV/AIDS epidemic.2
Population sequencing of plasma viruses only detects the most
abundant viral variants infecting each subject.3,4 Thereby, clini-
cians might miss potentially relevant information when making
treatment decisions and public health estimations underestimate
the burden of HIV-1 drug resistance. Next-generation sequencing
platforms detect minority viral variants with higher sensitivity, but
the clinical relevance of this is under discussion.
NNRTIs are often prescribed as first-line ART as efavirenz is
a recommended third drug in all treatment guidelines and nevir-
apine is one of the most affordable drugs in resource-limited set-
tings.5 – 8 These drugs are highly efficacious, but have a low genetic
barrier to resistance; even HIV-1 with a single mutation can
become fully resistant to NNRTIs.1 The small impact of most
NNRTI resistance mutations on HIV-1 replicative capacity allows
their persistence in the virus population of the infected subjects9
and their transmission to newly infected subjects. Using popula-
tion sequencing, between 5% and 15% of new HIV-1 infections in
Europe and the USA occur with an NNRTI-resistant virus.10,11 An
additional fraction of ART-naive subjects harbour minority
drug-resistant variants, which could also be transmitted or be
spontaneously generated in the absence of ART exposure.12 – 14
The best available evidence of the clinical relevance of minority
NNRTI-resistant HIV-1 variants to date is a systematic review and
pooled analysis of 10 published studies including 1263 ART-naive
subjects who initiated first-line NNRTI-containing ART with drug-
susceptible HIV-1 according to population sequencing.15 In that
study, detection of pre-existing minority drug-resistant HIV-1
variants (MVs) more than doubled the risk of virological failure
to first-line ART, showing a direct dose–effect relationship
between the level of MVs and the risk of virological failure. This
analysis, however, pooled studies with heterogeneous designs,
different MV detection techniques and inconsistent results.
To further clarify the impact of MVs on the virological outcomes
of first-line NNRTI-containing ART in the light of these previous
data, we designed a large European case–control study including
standard operating procedures for data collection, centralized
cDNA synthesis and 454 pyrosequencing and duplicate 454 bio-
informatic analysis of MVs, all blinded for clinical outcomes.
Methods
Study objectives
This study sought to investigate the ability of a single, pre-ART, ultrasensi-
tive HIV-1 genotypic test using 454 pyrosequencing (454 Life Sciences/
Roche Diagnostics) to predict virological failure to first-line ART including
two NRTIs and one NNRTI. Additional objectives were to evaluate the
consistency of the observations across different subsets of subjects and
to assess the presence of a dose–response relationship between muta-
tional load and risk of virological failure.
Study design and participants
This was a case–control study nested within seven prospective European
HIV-1 observational cohorts: Swiss HIV Cohort Study (SHCS), EuroSIDA
Study in EuroCoord (EuroSIDA), Italian Cohort of Antiretroviral-Naive
Patients (ICONA), German Competence Network (KompNet), Arevir
Platform, ANRS CO3 Aquitaine Cohort (Aquitaine) and Royal Free Hospital
(RFH) cohort. Clinical data were extracted from these cohorts using a
standard operating procedure (see the Supplementary data available at
JAC Online).
The study population included ART-naive subjects initiating ART with two
NRTIs plus one NNRTI and achieving a viral load ≤50 copies/mL within the
first 6 months following ART initiation. In addition, subjects had to have one
stored plasma sample with HIV-1 RNA levels ≥10000 copies/mL within
6 months prior to ART initiation and ≥3 months of virological follow-up
after achieving virological suppression. Subjects with any pre-ART IAS-USA
(March 2013)1 NNRTI or NRTI resistance mutation detected by population
sequencing or with NNRTI/NRTI mutations at a frequency .25% by 454
pyrosequencing were excluded.
Cases were subjects developing virological failure, defined as two
consecutive HIV-1 RNA measurements .200 copies/mL after achieving
HIV-1 RNA ≤50 copies/mL. Virological failure had to occur while the
person was still receiving the initial NNRTI therapy. The first of the two
HIV-1 RNA values .200 copies/mL was taken as time of the event.
Controls were subjects selected from the same cohort whose HIV-1 RNA
was still ≤200 copies/mL at a time matching the time of virological failure
for the corresponding case. A minimum of two matched controls were
chosen for every case. We applied the concept of case–control studies
of dynamic populations for our case–control sampling;16 thus, the same
patient can be included in several case–control sets.
Plasma sample processing, RT–PCR and 454
pyrosequencing
Archived plasma samples with HIV-1 RNA levels ≥10000 copies/mL and
collected from the different cohorts within 6 months prior to ART initiation
were shipped to Utrecht Medical Centre (Utrecht, The Netherlands), where
cDNA was generated using random hexamers as primers. cDNAs were
then shipped to the Institut fu¨r Immunologie und Genetik (Kaiserslautern,
Germany), where 454 amplicons were immediately prepared and
pyrosequenced in batches of 80 samples each in a 454 FLX Genome
Sequencer using Titanium chemistry. Amplicons used for this analysis
included amplicons A (protease), B, C and D (reverse transcriptase) from
the 454/Roche HIV-1 Genotyping Kit v2 plus one additional amplicon
designed specifically for this study (amplicon E), which covered the main
NNRTI mutations (Figure S1). Of note, amplicon A was amplified but not
sequenced, as protease data were considered not relevant for the present
study. cDNA synthesis and 454 processing were performed blinded for
clinical outcomes.
Data analysis
454 pyrosequencing sff files were analysed in parallel at the IrsiCaixa AIDS
Research Institute (Badalona, Catalonia, Spain) and University Hospital
Zurich (Zurich, Switzerland), blinded for clinical outcomes. Sequences
were demultiplexed using both 5′ and 3′ multiple identifier barcodes.
Roche’s proprietary Amplicon Variant Analyzer software version 2.7 was
used to call drug resistance mutations, based on the consensus alignment
information for each sample, using the HIV-1 HXB2 clonal sequence
(GenBank ID: K03455.1) as reference. A variant list containing all
IAS-USA drug resistance mutations1 was used. Mutants had to be
well balanced (their frequency in forward and reverse reads had to be
comprised within one log ratio) and to have been identified from a total
of ≥300 reads to be considered evaluable; otherwise, the codon was con-
sidered WT. A sample was defined to have a detected MV if 1%–25% of
the virus population showed that variant. The analyses of both centres
showed identical results (Figure S2).
The prevalence of detected MVs in cases and controls was compared
using the x2 test. Univariable and multivariable logistic regression analyses
were used to estimate ORs of virological rebound according to the
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prevalence of MVs. Separate models were constructed for: (i) the presence
of at least one IAS-USA 2013 reverse transcriptase inhibitor (RTI) MV; (ii)
the presence of at least one IAS-USA 2013 NRTI MV; (iii) the presence of
at least one IAS-USA 2013 NNRTI MV; and (iv) mutational load. The latter
was calculated by multiplying the mutant frequency in the virus popula-
tion by the HIV-1 RNA levels detected in the same sample and expressed
as mutant copy number/mL. If more than one MV was detected in the
same subject, the exposure variable ‘mutational load’ was calculated by
adding the copy number/mL of all mutants detected. For the analysis of
risk, mutational load was evaluated as a categorical variable, i.e. 0,
400–1000 and .1000 copies/mL, cut-offs chosen a priori on the basis
of previously published results.15 All multivariable estimates were adjusted
for factors included in the multivariable models shown in Table 2.
Additional sensitivity analyses were performed by including 245 unique
samples (each patient was included in the analysis only once) and after
excluding sequences containing aligned in-frame stop codons.
Results
Subjects’ disposition
Clinical data were obtained from a total of 3355 ART-naive patients
from seven prospective European HIV-1 observational cohorts, all
started ART containing two NRTIs and efavirenz or nevirapine,
achieving viral suppression ≤50 HIV-1 RNA copies/mL plasma,
and providing a genotypic HIV-1 drug resistance test prior to first-
line ART, leading to the extraction of 366 patients (Figure 1): 12
from Arevir, 33 from Aquitaine, 14 from EuroSIDA, 75 from
ICONA, 31 from KompNet, 78 from the RFH cohort and 123
from the Swiss HIV Cohort Study. One hundred and twenty-one
(33%) samples were excluded from downstream analyses due
to the following reasons: cDNA synthesis failed in 11 (3%) sam-
ples; 454 sequencing failed in 22 (6%) samples; NNRTI mutations
were found at ≥25% frequency by 454 pyrosequencing in 23
(6%) pre-ART samples; demographic data could not be provided
by the cohort in 5 (1%) samples; and an additional 60 (16%) had
to be excluded due to incomplete case–control sets. The 245
included and 116 excluded patients (for whom demographic
data were available) showed no differences in terms of age,
gender, ethnicity and mode of transmission. In contrast, viral
load was significantly lower in the excluded patients compared
with the included patients [4.77 (4.42–5.11) versus 4.91 (4.58–
5.32), median (IQR), log10 HIV-1 RNA copies/mL plasma,
P¼0.003]. This was caused by the fact that cDNA synthesis or
454 pyrosequencing failed predominantly in those samples
with lower viral loads.
Applying the concept of case–control studies of dynamic
populations for our case–control sampling,16 i.e. allowing the
same person/sample to be used as control for more than one
case, 260 samples (76 cases and 184 matched controls) were
analysed. There were 44 cases with two matched controls and
32 cases with three matched controls. In a sensitivity analysis,
we used the 245 unique samples.
Number of patients*
N = 3355
Samples extracted
n = 366 samples
n = 422 total samples**
Samples excluded, n = 121 (33%)
- cDNA ampliﬁcation failed, n = 11 (3%)
- 454 pyrosequencing failed, n = 22 (6%)
- NNRTI or NRTI mutations representing ≥25% of the
virus population found by 454, n = 23 (6%)
- Demographic data not provided, n = 5 (1%)
- Incomplete case–control set, n = 60 (16%)****
Samples included
n = 245 samples
n = 260 total samples***
Cases, n = 76
44 cases with 2 controls
32 cases with 3 controls
Controls, n = 184
Arevir, n = 12 (N = 419)  
Aquitaine, n = 33 (N = 203)  
EuroSIDA, n = 14 (N = 34)  
ICONA, n = 75 (N = 279)  
KompNet, n = 31 (N = 982)  
RFH, n = 78 (N = 604)  
SHCS, n = 123 (N = 834)  
Figure 1. Subject disposition and scheme of the study design. MVs were analysed by next-generation sequencing in plasma samples with HIV-1 RNA
levels≥10000 copies/mL collected within 6 months prior to ART initiation. *ART-naive patients in the cohorts starting ARTcontaining two NRTIs and one
NNRTI (efavirenz or nevirapine), achieving viral suppression≤50 HIV-1 RNA copies/mL plasma and providing a genotypic HIV-1 drug resistance test prior
to first-line ART. **Three hundred and sixty-six samples from 366 different patients were extracted from the different cohorts. Since several patients were
matched controls in more than one case–control set, the total number of samples was 422. ***The main analyses were performed on 260 samples; a
sensitivity analysis was performed on 245 unique samples. ****The exclusion of 61 patients due to technical challenges, NNRTI or NRTI mutations
representing ≥25% of the virus population or missing demographic data led to the exclusion of an additional 60 samples since certain case–control
sets were subsequently incomplete.
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Table 1. Baseline characteristics of study population according to detection of MVs in plasma samples collected prior to first-line NNRTI-based ART
≥1 IAS MV, N¼55 No MVs, N¼205 P Total, N¼260
Age (years) 0.776
median (IQR) 36 (26–41) 33 (24–43) 34 (24–42)
Gender, n (%) 0.050
female 6 (10.9) 47 (22.9) 53 (20.4)
Ethnicity, n (%) 0.143
white 39 (70.9) 131 (63.9) 170 (65.4)
black 3 (5.5) 6 (2.9) 9 (3.5)
Asian 2 (3.6) 5 (2.4) 7 (2.7)
other 11 (20.0) 63 (30.7) 74 (28.5)
Mode of HIV transmission, n (%) 0.382
MSM 27 (49.1) 77 (37.6) 104 (40.0)
heterosexual 13 (23.6) 82 (40.0) 95 (36.5)
intravenous drug use 6 (10.9) 26 (12.7) 32 (12.3)
other/unknown 9 (16.4) 20 (9.8) 29 (11.2)
HIV-1 subtype, n (%) 0.276
A 1 (1.8) 7 (3.4) 8 (3.1)
B 40 (72.7) 151 (73.7) 191 (73.5)
C 3 (5.5) 10 (4.9) 13 (5.0)
D 0 (0.0) 1 (0.5) 1 (0.4)
F 2 (3.6) 3 (1.5) 5 (1.9)
G/J 3 (5.5) 7 (3.4) 10 (3.8)
CRF01_AE 0 (0.0) 9 (4.4) 9 (3.5)
CRF01_AG 4 (7.3) 6 (2.9) 10 (3.8)
Calendar year of starting NNRTI 0.250
median (IQR) 2004 (2002–06) 2003 (2003–06) 2003 (2002–06)
Time from sample to ART initiation (months) 0.310
median (IQR) 2 (0–4) 2 (0–4) 2 (0–4)
CD4+ count at ART initiation (cells/mm3) 0.717
median (IQR) 261 (196–326) 258 (173–371) 259 (176–353)
HIV-1 RNA at ART initiation (log10 copies/mL) 0.995
median (IQR) 4.92 (4.55–5.36) 4.90 (4.49–5.32) 4.91 (4.58–5.33)
NNRTI started, n (%) 0.962
nevirapine 9 (16.4) 33 (16.1) 42 (16.2)
efavirenz 46 (83.6) 172 (83.9) 218 (83.8)
NRTI pair started, n (%) 0.040
recommended: ABC/3TC or TDF/FTC 19 (34.5) 62 (30.2) 81 (31.2)
alternative: ZDV/3TC or TDF/3TC 26 (47.3) 106 (51.7) 132 (50.8)
not recommended 10 (18.2) 37 (18.0) 47 (18.1)
Cohort, n (%) 0.340
Arevir 0 (0.0) 6 (2.9) 6 (2.3)
Aquitaine 3 (5.5) 25 (12.2) 28 (10.8)
EuroSIDA 0 (0.0) 0 (0.0) 0 (0.0)
ICONA 11 (20.0) 40 (19.5) 51 (19.6)
KompNet 5 (9.1) 9 (4.4) 14 (5.4)
RFH 12 (21.8) 48 (23.4) 60 (23.1)
Swiss HIV Cohort Study 24 (43.6) 77 (37.6) 101 (38.8)
IAS-USA, IAS-USA HIV-1 drug resistance mutation list (March 2013 update); ABC, abacavir; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine;
FTC, emtricitabine; ZDV, zidovudine.
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Subjects’ characteristics
Subjects were mostly male, Caucasian and infected through
sexual intercourse with mostly HIV-1 subtype B (Table 1). Their
median age was 34 years and the median calendar year of ART
initiation was 2003. They began ART with a median CD4+ count
of 259 cells/mm3 counts and median HIV-1 RNA levels of 4.9 log
copies/mL plasma. Most of them (83.9%) started with efavirenz.
The NRTI backbone consisted of drugs currently considered alter-
native in treatment guidelines (zidovudine/lamivudine or tenofo-
vir/lamivudine) in 50.8% and currently recommended NRTIs
(tenofovir disoproxil fumarate/emtricitabine or abacavir/lamivu-
dine) in 31.2%; 18.1% began with NRTI combinations that are
no longer recommended (e.g. including didanosine, stavudine,
or tenofovir in combination with zidovudine). Baseline
Table 2. Factors associated with virological failure
Cases, N¼76 Controls, N¼184
ORs of viral rebound .200 RNA copies/mL plasma
unadjusted OR (95% CI) P adjusteda OR (95% CI) P
Gender, n (%)
male 54 (71.1) 153 (83.2) 1.00 1.00
female 22 (28.9) 31 (16.8) 2.01 (1.07–3.77) 0.029 1.61 (0.73–3.53) 0.239
Ethnicity, n (%)
non-black 69 (90.8) 182 (98.9) 1.00 1.00
black 7 (9.2) 2 (1.1) 9.23 (1.87–45.53) 0.006 13.62 (2.25–82.49) 0.004
HIV-1 subtype, n (%)
B 52 (68.4) 139 (75.5) 1.00 1.00
non-B 24 (31.6) 45 (24.5) 1.43 (0.79–2.57) 0.238 1.28 (0.64–2.59) 0.484
Calendar year of starting ART, median (IQR)
per more recent 2003 (2001–05) 2004 (2002–06) 0.88 (0.79–0.97) 0.010 0.85 (0.72–1.01) 0.072
Time from sample to ART initiation, median (IQR)
per month longer 2.97 (1.21–5.02) 1.61 (0.00–3.31) 1.04 (1.00–1.08) 0.038 1.07 (1.02–1.12) 0.006
HIV-1 RNA at NNRTI initiation, median (IQR)
per log10 copies/mL higher 4.85 (4.54–5.30) 4.91 (4.50–5.36) 0.94 (0.58–1.54) 0.817 1.26 (0.68–2.33) 0.466
NNRTI started, n (%)
nevirapine 21 (27.6) 21 (11.4) 1.00 1.00
efavirenz 55 (72.4) 163 (88.6) 0.34 (0.17–0.66) 0.002 0.43 (0.18–1.02) 0.055
NRTI backbone started, n (%)
recommended: ABC/3TC or TDF/FTC 17 (22.4) 64 (34.8) 1.00 1.00
alternative: ZDV/3TC or TDF/3TC 36 (47.4) 96 (52.2) 1.41 (0.73–2.73) 0.304 0.84 (0.30–2.32) 0.732
not recommended 23 (30.3) 24 (13.0) 3.61 (1.65–7.89) 0.001 2.39 (0.74–7.69) 0.145
Detection of ≥1 IAS-USA MV prior to ART, any RTI, n (%)
no 52 (68.4) 153 (83.2) 1.00 1.00
yes 24 (31.6) 31 (16.8) 2.28 (1.23–4.23) 0.009 2.75 (1.35–5.60) 0.005
Detection of ≥1 IAS-USA NRTI MV prior to ART, n (%)
no 68 (89.5) 175 (95.1) 1.00 1.00
yes 8 (10.5) 9 (4.9) 2.29 (0.85–6.17) 0.102 2.27 (0.76–6.77) 0.140
Detection of ≥1 IAS-USA NNRTI MV prior to ART, n (%)
no 57 (75.0) 158 (85.9) 1.00 1.00
yes 19 (25.0) 26 (14.1) 2.03 (1.04–3.94) 0.037 2.41 (1.12–5.18) 0.024
Mutational load (RNA copies/mL), n (%)
0 52 (68.4) 153 (83.2) 1.00 1.00
400–1000 6 (7.9) 8 (4.3) 2.21 (0.73–6.66) 0.160 2.58 (0.68–9.73) 0.162
.1000 18 (23.7) 23 (12.5) 2.30 (1.15–4.60) 0.018 2.81 (1.26–6.24) 0.011
IAS-USA, IAS-USA HIV-1 drug resistance mutation list (March 2013 update); ABC, abacavir; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine;
FTC, emtricitabine; ZDV, zidovudine.
aAdjusted for calendar year of starting first-line ART, time from sample to ART initiation, viral load at ART initiation, NRTI pair started, NNRTI started,
ethnicity, HIV-1 subtype, gender and cohort study.
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characteristics were evenly distributed between subjects with or
without MVs with two exceptions: MVs were less frequently
observed in women (P¼0.05), slightly more frequent in subjects
receiving currently recommended NRTIs and slightly less frequent
in subjects receiving currently alternative NRTIs (P¼0.04).
MVs
MVs were analysed by next-generation sequencing in plasma
samples with a median of 4.91 log10 HIV-1 RNA copies/mL
plasma collected 2 (IQR 0 –4) months prior to ART initiation
(Table 1). Due to amplicon overlap, all relevant amino acid
positions in the reverse transcriptase were covered by ≥1000
sequence reads, with median coverage ranging from ≥1500 to
5000 sequence reads (Figure S3). MVs were detected in 55
(21%) subjects: 17 (7%) to NRTIs and 45 (17%) to NNRTIs at
frequencies of 1.1%–24.4% (Table S1). Overall, MVs were more
frequently observed in cases (24/76; 31.6%) than in controls
(31/184; 16.8%) (x2 test, P¼0.009; Table 2). All but three subjects
with MVs harboured only one MV. The most frequently observed
MVs were M184I (3%), V75I (1.5%) and L210W (1%) for NRTIs
and V90I (5%), V106I (4%), M230I (3%), V108I (2%) and E138K
(2%) for NNRTIs (Figure 2). The study was not powered to detect
significant differences in the prevalence of individual mutations
among groups.
Factors associated with virological failure
After adjusting for calendar year of starting first-line ART, time
from sample to ART initiation, HIV-1 RNA levels at ART initiation,
specific NRTI pair started, NNRTI started, ethnicity, HIV-1 subtype,
gender and cohort of enrolment, detection of at least one
IAS-USA 2013 MV conferring resistance to RTIs was associated
with an increased risk of virological failure to first-line,
NNRTI-containing ART [OR¼2.75 (95% CI 1.35–5.60), P¼0.005]
(Table 2). Similar associations were observed for detection of at
least one IAS-USA 2013 MV resistant to NNRTIs alone [OR¼2.41
(95% CI 1.12–5.18), P¼0.024] or NRTIs alone [OR¼2.27 (95% CI
0.76–6.77), P¼0.140] (Table 2), although the latter did not reach
statistical significance.
There was a direct dose–effect relationship between the
mutational load of MVs and risk of virological failure. Subjects with
400–1000 MV copies/mL plasma had an intermediate risk
[OR¼2.58 (95% CI 0.68–9.73), P¼0.162] whereas those with
.1000 MV copies/mL plasma had the highest risk [OR¼2.81 (95%
CI 1.26–6.24), P¼0.011].
The magnitude of these associations was consistent in pre-
specified groups stratified by baseline NNRTI or NRTI used as
well as in the sensitivity analysis including 245 unique samples
[OR for at least one IAS-USA RTI MV¼2.69 (95% CI 1.30–5.57),
P¼0.008] (Table S2) and excluding sequences containing aligned
in-frame stop codons [OR for at least one IAS-USA RTI MV¼1.89
(95% CI 0.88–4.04), P¼0.103] (Table S3).
Other factors associated with increased risk of virological
failure included black ethnicity [OR¼13.62 (95% CI 2.25 –
82.49), P¼0.004] and time from sample to ART initiation
[OR¼1.07 (95% CI 1.02–1.12) per month longer, P¼0.006].
Discussion
In this large European case–control study, detection of low-
frequency mutations conferring resistance to RTIs was strongly
associated with a .2-fold increased risk of virological failure in
people initiating first-line ART with two NRTIs plus one NNRTI.
This association was consistent regardless of the NRTI backbone
started or whether nevirapine or efavirenz was commenced.
Moreover, there was a significant dose–effect relationship between
the mutational load of MVs and the risk of virological failure.
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Figure 2. IAS-USA 2013 mutations detected as minority drug resistance mutations by case–control status. Only P values ,0.2 are reported. Two
hundred and forty-five unique samples were included.
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Similar results were observed in the analyses focusing on the
effect associated with the detection of at least one NNRTI or
one NRTI mutation, although for the latter the association did
not reach statistical significance.
This study confirms and extends previous observations15,17 – 21
and to date provides the highest degree of evidence available that
low-frequency drug-resistant mutants do impair the efficacy of
ART including the NNRTIs nevirapine or efavirenz plus two NRTIs.
Interestingly, this was independent from the viral load prior to
ART, which was not different in cases and controls. It is also the
largest single study available using next-generation sequencing
for HIV-1 drug resistance genotyping.
We defined virological failure as a confirmed viraemia rebound
of .200 copies/mL after achieving HIV-1 RNA ≤50 copies/mL.
This definition excluded subjects who never achieved HIV-1 RNA
suppression and might have led to exclusion of people with
NNRTI-resistant MVs most strongly associated with drug resist-
ance, such as K103N and Y181C. Indeed, previous studies showed
that MVs such as K103N and Y181C strongly predicted early
virological failure and lack of HIV-1 RNA suppression.15,17 Thus,
our study design might lead to an underestimation of the impact
of MVs. However, we deliberately chose this definition to remove
patients with poor adherence, a factor associated with both drug
resistance and virological failure, which is difficult to control for in
analysis of observational data.
To avoid heterogeneity related to minority drug-resistant HIV-1
variant testing, cDNA synthesis, 454 amplicon generation and 454
pyrosequencing were centralized in two highly experienced
European centres, blinded for virological outcomes. Amplicon gen-
eration and sequencing is relatively complex with this platform and
testing in laboratories with different degrees of expertise could have
led to inconsistencies. Parallel analysis of raw 454 data in two inde-
pendent laboratories blinded for clinical outcomes achieved 100%
agreement, ruling out sequence interpretation biases.
The case–control design of this study does not allow a formal
estimate of the incidence of virological failure in the cohorts,
because the number of cases is fixed at the outset.
Nevertheless, we detected MVs more frequently than anticipated
(in 21% of subjects overall). In a previous pooled analysis of
studies,15 14% of subjects infected with WT HIV-1 by population
sequencing harboured minority NNRTI-resistant variants. The
most prevalent mutations in our population were V90I,
V106I and M230I for NNRTIs and M184I, V75I and L210W for
NRTIs. Mutations V90I and V106I are polymorphic accessory
mutations weakly selected by NNRTIs in vitro and in vivo. They
contribute to reduced susceptibility to etravirine in combination
with other mutations, but induce a small, if any, reduction in
efavirenz or nevirapine susceptibility even if detected as majority
variants.22 In a recent analysis of 4528 UK patients who com-
menced efavirenz or nevirapine with at least two NRTIs without
major drug resistance mutations, polymorphisms at codons 90
(mostly V90I), 98 (mostly A98S) and 103 (mostly K103R) were
each independently associated with increased risk of virological
failure.23 In combination with other mutations, V106I may
enhance the level of resistance to efavirenz.24 The other muta-
tions detected in our study are well known to reduce NNRTI
susceptibility. As our study was not powered to discern the effect
of individual mutations on the efficacy of first-line, NNRTI-
containing ART, it is uncertain whether any of the individual muta-
tions detected exerted a direct effect on NNRTI susceptibility or, in
contrast, were surrogate markers of other, perhaps more relevant
NNRTI resistance mutations present in the virus population below
the detection threshold of 454 pyrosequencing.
In our main analysis, we did not exclude sequences containing
stop codons, which may be a marker of poor sequence quality.
However, sequence quality or alignment problems were ruled
out by visual inspection of alignments. In addition, mutants
required a minimum coverage based on the Poisson probability
to detect rare events25 and an even representation in forward
and reverse reads to be considered real.26 Indeed, a sensitivity
analysis excluding sequences with stop codons provided similar
trends to those observed in the main analysis (Table S3), although
trends are non-significant, pointing out a possible role of stop
codon-containing sequences in resistance analysis. In fact, the
most prevalent mutations in our study correspond to G-to-A
mutations and could share a generation mechanism with stop
codons, both resulting from APOBEC3G/F editing,27,28 which is
not related to sequence quality. This phenomenon is being further
investigated by our group.
As a limitation, we did not collect enough genotypic tests at
virological failure to investigate whether the pre-ART MVs were
enriched at viral rebound (Table S4). However, such a relationship
might not be linear, as the fate of pre-ART variants may also be
determined by the specific treatment received and by complex
mutational interactions where not only resistance but also fitness
and genetic barriers to resistance would play important roles. In
previous studies in antiretroviral-naive subjects,21 NNRTI regimen
choice and pre-existing minority NNRTI-resistant variants were
both associated with the probability and type of resistance
mutations detected after virological failure. Also, our study lacked
a formal evaluation of ART adherence given that cohorts do not
uniformly collect such data. In previous studies,19,20 the presence
of minority NNRTI resistance mutations and NNRTI adherence
were found to be independent predictors of virological failure,
but also to modify each other’s effects on virological failure. By
including people who achieved viral suppression on their initial
ART, we should have reduced the inclusion of poorly adherent
subjects.
Other factors associated with virological failure in our study
were black ethnicity and longer time from sample to ART initiation.
Previous studies have linked black ethnicity with virological
failure through impaired socioeconomic status and adherence29
and/or presence of cytochrome P450 polymorphisms associated
with a slow metabolizer profile, which lead to increased neurotox-
icity by efavirenz.30,31 The association between longer time from
sample to ART initiation, again, might be a marker of poor adher-
ence, overall quality of care or some other unrecognized factors.
Indeed, it is conceivable that initiation of ART might be delayed in
persons who are perceived to be potentially non-adherent.
However, the magnitude of the OR is small and therefore this
association is probably not clinically relevant.
In summary, this study confirms and extends previous reports
and provides strong evidence that MVs in the reverse transcript-
ase impair the efficacy of first-line ART including efavirenz
or nevirapine. Our findings, together with those previously
published, suggest that ultrasensitive HIV-1 genotyping could
have a role in improving the outcomes of ART including
NNRTIs. Consequently, they also provide a rationale for including
ultrasensitive genotyping in HIV-1 resistance surveillance
programmes.
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